REGENXBIO Inc.
RGNX
$7.77
$0.010.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 104.54% | 91.30% | 74.95% | 80.70% | -7.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 104.54% | 91.30% | 74.95% | 80.70% | -7.66% |
| Cost of Revenue | 2.69% | -3.83% | -3.29% | -8.93% | -9.15% |
| Gross Profit | 50.77% | 52.46% | 45.76% | 53.04% | 9.92% |
| SG&A Expenses | 15.70% | 0.78% | -4.97% | -11.71% | -18.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -79.31% | 538.67% | 179.28% | 176.97% | 117.88% |
| Total Operating Expenses | 5.43% | -2.52% | -3.50% | -9.43% | -11.31% |
| Operating Income | 30.29% | 35.47% | 32.25% | 39.49% | 12.55% |
| Income Before Tax | 14.63% | 25.55% | 27.22% | 39.42% | 13.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.63% | 25.50% | 27.17% | 39.38% | 13.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.63% | 25.50% | 27.17% | 39.38% | 13.81% |
| EBIT | 30.29% | 35.47% | 32.25% | 39.49% | 12.55% |
| EBITDA | 32.30% | 37.75% | 34.19% | 41.76% | 12.98% |
| EPS Basic | 18.59% | 31.22% | 34.76% | 47.12% | 23.49% |
| Normalized Basic EPS | 17.77% | 29.44% | 33.15% | 45.95% | 23.22% |
| EPS Diluted | 18.59% | 31.22% | 34.79% | 47.18% | 23.57% |
| Normalized Diluted EPS | 17.77% | 29.44% | 33.15% | 45.95% | 23.22% |
| Average Basic Shares Outstanding | 4.18% | 7.47% | 10.98% | 14.91% | 13.19% |
| Average Diluted Shares Outstanding | 4.22% | 7.50% | 11.02% | 14.95% | 13.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |